Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,

JNJ-6143 demonstrated promising PSA and tumor response rates with an encouraging safety profile in heavily pretreated mCRPC, including across genomic subgroups.

Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.

Updated CAPItello-281 data showed a clinically meaningful benefit in OS when capivasertib was added to abiraterone and ADT in PTEN-deficient mHSPC.

Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.

The PROTEUS substudy addresses a key limitation of the main study, which had no surgery-alone control arm.

A comprehensive guide to the top data in genitourinary oncology presented at ESMO 2026.

Brian I. Rini, MD, FASCO, explains why LITESPARK-012’s negative triplet results still offer lessons on drug delivery and building on first-line RCC doublets.